MannKind's revenue momentum is accelerating, with 2026Q2 revenue up 42.9% YoY to $109.4M, driven by Tyvaso DPI royalties and Afrezza growth, yet operating leverage has reversed as SG&A surged 84.5% YoY to $58.3M, pushing operating income to a -$350K loss. The ...
Price trend, volume and key moving averages
Trailing total returns as of 9/25/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 5, 2026 | -$0.06-700.0% vs -$0.01 | $109M+1.2% vs $108M |
Q2 2026 May 6, 2026 | -$0.05-150.0% vs -$0.02 | $90M-14.4% vs $105M |
Q1 2026 Feb 26, 2026 | -$0.05-400.0% vs -$0.01 | $112M+14.7% vs $98M |
Q4 2025 Nov 5, 2025 | $0.03+200.0% vs $0.01 | $82M-17.7% vs $100M |
MannKind NASDAQ: MNKD CFO Chris Prentiss outlined the company's commercial and development priorities at the H.C. Wainwright Global Investment Conference, emphasizing execution following three major 2026 catalysts: expanded pediatric approval for Afrezza, the launch of FUROSCIX ReadyFlow, and Phase 1b data for MNKD-201 in idiopathic pulmonary fibrosis, or IPF.
MannKind Corporation (NASDAQ:MNKD) shares are trading lower on Wednesday as traders react to the company's entry into a licensing and collaboration deal tied to an inhaled, rapid-acting GLP-1 program.
Collaboration combines Rose Pharma investigational rapid-acting GLP-1 receptor agonist with MannKind's Technosphere ® inhalation technology MannKind to receive an equity interest and potential royalties while providing pharmaceutical development and manufacturing support through completion of a Phase 1b clinical study DANBURY, Conn. and WESTLAKE VILLAGE, Calif.
DANBURY, Conn. and WESTLAKE VILLAGE, Calif.
Benchmark MNKD against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for MannKind Corporation (MNKD)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $3.29 | $1.05B | 164.50 | 22.23% | 1.68% | — | — | |
| $472.21 | $20.04B | 16.95 | 10.61% | 41.56% | 20.18% | — | |
| $121.55 | $26.35B | -18.96 | 66.73% | -76.94% | -111.26% | — | |
| $22.18 | $3.8B | 9.69 | 11.87% | 33.42% | 32.39% | — | |
| $62.28 | $5.17B | 8.01 | 114.51% | -3.8% | — | — | |
| $14.77 | $1.45B | -2.53 | 20.13% | -81.79% | — | — |
MannKind Corporation (MNKD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
MannKind Corporation (MNKD) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 5, 2026·SEC
Jul 24, 2026·SEC
Jun 2, 2026·SEC
Get notified when MNKD posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
MannKind Corporation (MNKD) stock FAQ — growth, dividends, profitability & financials explained
MannKind Corporation (MNKD) reported $393.6M in revenue for fiscal year 2025.
MannKind Corporation (MNKD) grew revenue by 22.2% over the past year. This is strong growth.
MannKind Corporation (MNKD) reported a net loss of $43.6M for fiscal year 2025.
MannKind Corporation (MNKD) had negative free cash flow of $18.6M in fiscal year 2025, likely due to heavy capital investments.
